ArticleCancer cell2016
Defining the Molecular Alterations of Ampullary Carcinoma.
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms.JAMA network open · 2026Article
- Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.International journal of molecular sciences · 2026Review
- Precursor Epithelial Subtypes of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasms (A-IPMN): Clinicopathological Features, Recurrence and Response to Adjuvant Chemotherapy.Annals of surgical oncology · 2024Article
- Predicting the unpredictable: a robust nomogram for predicting recurrence in patients with ampullary carcinoma.BMC cancer · 2024Article
- Immunohistochemical expression of beta-catenin in ampullary adenocarcinoma: a cross-sectional retrospective study.Annals of medicine and surgery (2012) · 2023Article
- Ampullary and pancreatic adenocarcinoma-a comparative study.Journal of gastrointestinal oncology · 2019Article
- KRAS, NRAS and BRAF analysis of ampullary adenocarcinoma classified using CK7, CK20, MUC1 and MUC2.Journal of gastrointestinal oncology · 2018Article
- Emerging molecular therapeutic targets for cholangiocarcinoma.Journal of hepatology · 2017Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ampullary carcinomas represent a group of heterogeneous tumors that can be histologically divided into two subtypes with distinct pathogenic and clinical characteristics. Yachida et al. (2016) and Gingras et al. (2016) now report the genomic landscape of ampullary carcinoma, providing insights into molecular drivers with clinical implications for diagnosis and therapeutics.
Indexed as
Identifiers
26859450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.